Inside MannKind’s Share Sale: A Routine Move, Not a Red Flag for Investors
Insider sale by MannKind’s chief people officer shows routine compliance, not a bearish signal – a potential floor price in the $6–$7 band while investors focus on the company’s biopharma pipeline and ESG‑aligned growth.
4 minutes to read